DOI QR코드

DOI QR Code

Medication Use Evaluation of Denosumab in Postmenopausal Women with Osteoporosis or Osteopenia

폐경 후 골다공증 및 골감소증 여성의 denosumab 약물 사용 평가

  • Lim, Seon-Hye (Department of Pharmacy, Chungnam National University Hospital) ;
  • Jung, Woo Jin (College of Pharmacy, Chungnam National University) ;
  • Chae, Jung-woo (College of Pharmacy, Chungnam National University) ;
  • Kang, Chan (Department of Orthopedic Surgery, Chungnam National University Hospital) ;
  • Yun, Hwi-yeol (College of Pharmacy, Chungnam National University)
  • 임선혜 (충남대학교병원 약제부) ;
  • 정우진 (충남대학교 약학대학) ;
  • 채정우 (충남대학교 약학대학) ;
  • 강찬 (충남대학교병원 정형외과) ;
  • 윤휘열 (충남대학교 약학대학)
  • Received : 2020.07.31
  • Accepted : 2020.09.11
  • Published : 2020.09.30

Abstract

Background: The indication of denosumab for osteoporosis was expanded from second-line to first-line therapy in 2019. The aim of this study was to evaluate the efficacy of denosumab as both first- and second-line therapy in postmenopausal women with osteoporosis and osteopenia with risk factors by using the Fracture Risk Assessment Tool (FRAX). Methods: We conducted a medication use evaluation of denosumab in 98 patients who had been treated three or more times for osteoporosis or osteopenia at Chungnam National University Hospital from July 1st, 2017 to January 31st, 2020. Risk factors were identified using quantitative N-gram analyses of FRAX estimations. Patient information, including menopause status and results of bone mineral density tests (T-score), was obtained from electronic medical records. Results: Age, body mass index (BMI), prior medication use, and T-score were identified as risk factors and were included as variables in the evaluation of denosumab use. Since no significant differences were detected between groups, denosumab is likely effective regardless of age or BMI. In addition, no significant difference was detected in T-scores following denosumab treatment, between groups who took bisphosphonates and selective estrogen receptor modulators (SERMs) with denosumab as first-line therapy for postmenopausal osteoporosis. Denosumab may, therefore, be effective as second-line therapy. Conclusion: Efficacy of denosumab was evaluated in postmenopausal women with osteoporosis. Denosumab may be used as first- and second-line therapy regardless of age, BMI, and prior use of bisphosphonates and SERMs.

Keywords

References

  1. Kanis, JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Who Study Group. Osteoporos Int 1994;4(6):368-81. https://doi.org/10.1007/BF01622200
  2. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285(6):785-95. https://doi.org/10.1001/jama.285.6.785
  3. Yun HG, Definition and epidemiology of osteoporosis, In: Yun HG, Physician's guide for osteoporosis 2018. Seoul: Korean society for bone and mineral research, 2018: 12-90
  4. Heaney RP, Abrams S, Dawson-Hughes B, et al. Peak bone mass. Osteoporos Int 2000;11(12):985-1009. https://doi.org/10.1007/s001980070020
  5. Kim JC, Oh MJ, Park MS, Kil MD, Kim C. Bone mineral density of Korean women and comparison of bone mineral density in pre- and postmenopausal women. Korean J Obstet Gynecol 1996;39(10):1905-12.
  6. Riggs BL, Khosla S, Melton LJ 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002;23(3):279-302. https://doi.org/10.1210/er.23.3.279
  7. Lash RW, Nicholson JM, Velez L, Van Harrison R, McCort J. Diagnosis and management of osteoporosis. Prim Care 2009;36(1):181-98. https://doi.org/10.1016/j.pop.2008.10.009
  8. Centre for Metabolic Bone Diseases. FRAX. Available from https://www.sheffield.ac.uk/FRAX/. Accessed July 29, 2020.
  9. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2016. Endocr Pract 2016;22(Suppl 4):1-42.
  10. Health Insurance Review & Assessment Service. Institutional Statute: insurance recognition standards July 2020. Available from https://www.hira.or.kr, Accessed August 26, 2020.
  11. Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2019;104(5):1595-622. https://doi.org/10.1210/jc.2019-00221
  12. Cavnar W.B., Trenkle J.M., N-gram-based text categorization ngram-based text categorization, Proc. Third Annu. Symp. Doc. Anal. Inf. Retr. 2001:1-14.
  13. Papapoulos S, Lippuner K, Roux C, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension study. Osteoporos Int 2015;26(12):2773-83. https://doi.org/10.1007/s00198-015-3234-7
  14. Koh JM, Chung DJ, Chung YS, et al. Assessment of denosumab in Korean postmenopausal women with osteoporosis: Randomized, double-blind, placebo-controlled trial with open-label extension. Yonsei Med J 2016;57(4):905-14. https://doi.org/10.3349/ymj.2016.57.4.905
  15. Nakamura T, Matsumoto T, Sugimoto T, Shiraki M. Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis. Osteoporos Int 2012;23(3):1131-40. https://doi.org/10.1007/s00198-011-1786-8